Table 4.

Cross-case synthesis: structural contrasts between the EU and US frameworks for orphan medical devices.

Dimension	European Union (EU)	United States (US)	Analytical implication
Approval timing	CE marking typically granted earlier (e.g., Argus II, 2011; Melody, 2006), often based on limited early data.	HDE approvals granted later (e.g., Argus II, 2013; Melody, 2010; EXCOR, 2011) but under a codified humanitarian pathway.	Europe offers faster entry but without legal orphan status; the US provides structured flexibility through law, though with initial delays.
Standard of proof	“Expected clinical benefit” and PMCF; no defined orphan-device threshold.	“Probable benefit” standard under HDE, with mandatory post-approval studies and IRB oversight.	US approach formalizes evidentiary pragmatism; EU relies on case-by-case interpretation, producing uncertainty for developers.
Economic incentives	No orphan-specific financial instruments; SMEs face high MDR recertification costs.	Profit prohibited under HDE except for pediatric indications (post-2007 amendment), improving viability for niche devices.	US framework includes bounded commercial feasibility; EU offers none, disincentivizing innovation among SMEs.
Continuity safeguards	No binding mechanism for continued supply or service; six-month withdrawal notice under MDR Art. 123.	No statutory obligation to ensure post-market continuity once a device becomes commercially nonviable.	Both systems lack ex poststewardship obligations; Argus II illustrates time-inconsistency and hold-up risk.
Reimbursement landscape	Fragmented national HTA and payer assessments; no EU-wide orphan-device coverage model.	CMS or private-payer coverage case-by-case; no automatic linkage to FDA approval.	In both systems, regulatory clearance ≠ market access; policy disconnect persists between evidence and payment.
Industrial structure	Sector dominated by SMEs (92%), limited lobbying power, vulnerable to regulatory cost shocks.	Larger diversified firms can cross-subsidize niche products; SMEs remain fragile but benefit from clearer FDA interlocution.	The EU framework disproportionately penalizes SMEs; the US model offers predictability but not profitability.
Integration with rare-disease policy	Orphan devices not integrated into EU rare-disease plans or incentives under Regulation (EC) 141/2000.	HUD/HDE partially recognized within US rare-disease strategy but without reimbursement alignment.	Absence of a full continuum from designation → reimbursement → continuity undermines patient protection.
Ethical and systemic effect	Flexible ex ante (approval) but fragile ex post (continuity).	Structured ex ante (law) but incomplete ex post (coverage).	Structural asymmetry: EU codifies speed; US codifies safety. Neither ensures sustainability for patients dependent on orphan devices.